We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Alkermes Gets FDA Nod for Two Month Dose of Aristada
Read MoreHide Full Article
Alkermes plc (ALKS - Free Report) announced that the FDA has approved two-month Aristada (aripiprazole lauroxil) extended-release injectable suspension for the treatment of schizophrenia. The new two month dose is expected to be available in mid-June.
Alkermes’ share price increased 6.1% year to date outperforming the Zacks classified Medical - Biomedical and Genetics industry’s gain of 1.7%.
Consequently, Aristada is now approved in four doses and and three dosing duration options (441 mg, 662 mg or 882 mg once monthly, 882 mg once every six weeks and 1064 mg once every two months).
As a result, Aristada provides a number of options to help clinicians tailor treatment to the individual needs of their patients. The drug was originally approved in Oct 2015.
We note Aristada posted sales of $18 million in the first quarter of 2017, up compared with $5.6 million in the first quarter of 2016. Aristada is growing impressively in a long-acting injectable (LAI) market, evident from its improvement in the double digits.
However, in Mar 2017, Allergan plc announced that its supplemental New Drug Application (sNDA) Vraylar has been accepted for review by the FDA. Allergan is looking to get Vraylar’s label expanded to include new data, which supports the drug’s use as a maintenance treatment.
VIVUS’ loss per share estimates narrowed from 50 cents to 39 cents for 2017 in the last 30 days. The company posted positive earnings surprises in the trailing four quarters, with an average beat of 233.69%.
MEI Pharma’s estimates narrowed from loss per share of 1 cent to gain per share of 1 cent for 2017 in the last 30 days. The company posted positive earnings surprises in three of the four preceding quarters, with an average beat of 66.56%.
3 Stocks to Ride a 588% Revenue Explosion
At Zacks, we're mostly focused on short-term profit cycles, but the hottest of all technology mega-trends is starting to take hold...
By last year, it was already generating $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce ""the world's first trillionaires,"" but that should still leave plenty of money for those who make the right trades early. See Zacks' Top 3 Stocks to Ride This Space >>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Alkermes Gets FDA Nod for Two Month Dose of Aristada
Alkermes plc (ALKS - Free Report) announced that the FDA has approved two-month Aristada (aripiprazole lauroxil) extended-release injectable suspension for the treatment of schizophrenia. The new two month dose is expected to be available in mid-June.
Alkermes’ share price increased 6.1% year to date outperforming the Zacks classified Medical - Biomedical and Genetics industry’s gain of 1.7%.
Consequently, Aristada is now approved in four doses and and three dosing duration options (441 mg, 662 mg or 882 mg once monthly, 882 mg once every six weeks and 1064 mg once every two months).
As a result, Aristada provides a number of options to help clinicians tailor treatment to the individual needs of their patients. The drug was originally approved in Oct 2015.
We note Aristada posted sales of $18 million in the first quarter of 2017, up compared with $5.6 million in the first quarter of 2016. Aristada is growing impressively in a long-acting injectable (LAI) market, evident from its improvement in the double digits.
However, in Mar 2017, Allergan plc announced that its supplemental New Drug Application (sNDA) Vraylar has been accepted for review by the FDA. Allergan is looking to get Vraylar’s label expanded to include new data, which supports the drug’s use as a maintenance treatment.
Alkermes PLC Price
Alkermes PLC Price | Alkermes PLC Quote
Zacks Rank and Stocks to Consider
Alkermes carries a Zacks Rank #3 (Hold). Better-ranked stocks in the health care sector includes VIVUS, Inc. and MEI Pharma, Inc. (MEIP - Free Report) , both sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
VIVUS’ loss per share estimates narrowed from 50 cents to 39 cents for 2017 in the last 30 days. The company posted positive earnings surprises in the trailing four quarters, with an average beat of 233.69%.
MEI Pharma’s estimates narrowed from loss per share of 1 cent to gain per share of 1 cent for 2017 in the last 30 days. The company posted positive earnings surprises in three of the four preceding quarters, with an average beat of 66.56%.
3 Stocks to Ride a 588% Revenue Explosion
At Zacks, we're mostly focused on short-term profit cycles, but the hottest of all technology mega-trends is starting to take hold...
By last year, it was already generating $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce ""the world's first trillionaires,"" but that should still leave plenty of money for those who make the right trades early. See Zacks' Top 3 Stocks to Ride This Space >>